Surgery Partners(SGRY) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported full year net revenue of $3.3 billion, up 6.2% year-over-year, with same facility revenue growth of 4.9% [4][24] - Full year Adjusted EBITDA was $526 million, up 3.5% year-over-year, but below expectations, with an Adjusted EBITDA margin of 15.9%, reflecting 40 basis points of margin compression [4][25] - Fourth quarter revenue grew 2.4% to $885 million, with Adjusted EBITDA of $156.9 million and a margin of 17.7% [23][25] Business Line Data and Key Metrics Changes - The company performed nearly 670,000 surgical cases in 2025, a 2% increase from 2024, with same facility case growth of 1.3% in the fourth quarter [6][23] - Orthopedic cases grew significantly, with total joint replacements increasing by 15% in the fourth quarter and 19% year-to-date compared to the previous year [7] - The company faced challenges in three surgical hospital markets, which experienced slower case growth and shifts in payer mix, impacting overall performance [5][9] Market Data and Key Metrics Changes - The payer mix softened during the fourth quarter, with a decline in commercial patients compared to historical trends, primarily affecting surgical hospitals [24][41] - The company noted that the pressure on payer mix was concentrated in specific markets, with some competitors opting to limit access to Medicare Advantage patients [46][81] Company Strategy and Development Direction - The company remains committed to its growth strategy, focusing on organic growth, acquisitions, and optimizing its portfolio to enhance shareholder value [6][12] - A portfolio optimization strategy is underway, aimed at divesting non-core facilities and enhancing operational efficiency [13][15] - The company plans to continue investing in de novo facilities, with eight openings in 2025 and more in the pipeline, targeting high-growth markets [12][31] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in the second half of 2025 but expressed confidence in the long-term growth potential of the business [5][10] - The initial guidance for 2026 includes net revenue of $3.35 billion to $3.45 billion, reflecting single-digit growth, and at least $530 million in Adjusted EBITDA [16][33] - Management emphasized the need for improved execution and cost management to address near-term headwinds while remaining optimistic about structural growth opportunities [18][19] Other Important Information - The company authorized a share repurchase program of up to $200 million, reflecting confidence in future growth and capital allocation strategy [20][56] - New leadership has been appointed to support operational improvements in underperforming facilities [10][73] Q&A Session Summary Question: Challenges and Volume Outlook - A question was raised regarding the balance between conservative volume expectations and the belief in strong fundamentals [40] - Management responded by reiterating confidence in the growth algorithm and the value created within the healthcare system [41][42] Question: Payer Mix Dynamics - Inquiry about the payer mix situation and its impact on volumes, particularly regarding Medicare and commercial patients [40] - Management acknowledged the unique pressures faced in specific markets and expressed optimism about returning to a balanced payer mix [45][54] Question: Capital Deployment and Share Buyback - A question was posed about balancing capital deployment with the share buyback program [55] - Management clarified that the share buyback is part of a measured approach to maximize shareholder value while considering debt reduction [56][85] Question: Recovery of Surgical Hospital Markets - A question was asked about the recovery assumptions for surgical hospital markets [70] - Management indicated that while there are pressures, they do not expect a repeat of the previous year's challenges and are focused on turnaround plans [73][81]